Soluble CD80 as a therapeutic to reverse immune supression in cancer patients
US8956619B2 · kind B2 · utility
25Cited by
0References
4Claims
0Family size
Assignee
Inventor
Key dates
| Filing date | Oct 25, 2012 |
| Grant date | Feb 17, 2015 |
| Priority date | — |
| Expiry date | Oct 25, 2032 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC07K2319/30
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
The present invention provides for a therapeutic cancer treatment using a soluble CD80 fusion protein that binds to PDLL and inhibits PDLL-PD1 interactions thereby overcoming PDLL-induced immune suppression and restoring T cell activation.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.